Purdue Pharma announced that it has received FDA approval for a new 7.5mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII and for the use of two patches to facilitate dose adjustments during titration, with a total max dose from both patches of 20mcg/hour.
Butrans is a Schedule III partial opioid agonist indicated for the management of pain severe enough to require daily, around-the clock, long-term opioid treatment for which alternative treatment options are inadequate in adults ≥18 years. Buprenorphine is a partial agonist at mu opioid receptors, an antagonist at kappa-opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors. Its clinical actions result from binding to the opioid receptors.
The Butrans transdermal patch is already available in 5mcg/hour, 10mcg/hour, 15mcg/hour and 20mcg/hour strengths. The new dose is expected to launch in October 2014.
For more information call (888) 726-7535 or visit Butrans.com.